Jelisa Gallant1, Kathleen Chan1, Tim J Green2,3, Frank T Wieringa4, Shalem Leemaqz2, Rem Ngik5, Jeffrey R Measelle6, Dare A Baldwin6, Mam Borath7, Prak Sophonneary8, Lisa N Yelland2,9, Daniela Hampel10,11, Setareh Shahab-Ferdows10,11, Lindsay H Allen10,11, Kerry S Jones12, Albert Koulman12, Damon A Parkington12, Sarah R Meadows12, Hou Kroeun5, Kyly C Whitfield1. 1. Department of Applied Human Nutrition, Mount Saint Vincent University, Halifax, NS Canada. 2. South Australian Health and Medical Research Institute, Adelaide, SA, Australia. 3. School of Medicine, University of Adelaide, Adelaide, SA, Australia. 4. UMR-204, Institut de recherche pour le développement, UM/IRD/SupAgro, Montpellier, France. 5. Helen Keller International Cambodia, Phnom Penh, Cambodia. 6. Department of Psychology, University of Oregon, Eugene, OR, USA. 7. National Subcommittee for Food Fortification, Cambodia Ministry of Planning, Phnom Penh, Cambodia. 8. National Nutrition Programme, Maternal and Child Health Centre, Cambodia Ministry of Health, Phnom Penh, Cambodia. 9. School of Public Health, University of Adelaide, Adelaide, SA, Australia. 10. USDA, ARS Western Human Nutrition Research Center, University of California, Davis, CA, USA. 11. Department of Nutrition, University of California, Davis, CA, USA. 12. NIHR BRC Nutritional Biomarker Laboratory, MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
Abstract
BACKGROUND: Infantile beriberi-related mortality is still common in South and Southeast Asia. Interventions to increase maternal thiamine intakes, and thus human milk thiamine, are warranted; however, the required dose remains unknown. OBJECTIVES: We sought to estimate the dose at which additional maternal intake of oral thiamine no longer meaningfully increased milk thiamine concentrations in infants at 24 wk postpartum, and to investigate the impact of 4 thiamine supplementation doses on milk and blood thiamine status biomarkers. METHODS: In this double-blind, 4-parallel arm randomized controlled dose-response trial, healthy mothers were recruited in Kampong Thom, Cambodia. At 2 wk postpartum, women were randomly assigned to consume 1 capsule, containing 0, 1.2 (estimated average requirement), 2.4, or 10 mg of thiamine daily from 2 through 24 weeks postpartum. Human milk total thiamine concentrations were measured using HPLC. An Emax curve was plotted, which was estimated using a nonlinear least squares model in an intention-to-treat analysis. Linear mixed-effects models were used to test for differences between treatment groups. Maternal and infant blood thiamine biomarkers were also assessed. RESULTS: In total, each of 335 women was randomly assigned to1 of the following thiamine-dose groups: placebo (n = 83), 1.2 mg (n = 86), 2.4 mg (n = 81), and 10 mg (n = 85). The estimated dose required to reach 90% of the maximum average total thiamine concentration in human milk (191 µg/L) is 2.35 (95% CI: 0.58, 7.01) mg/d. The mean ± SD milk thiamine concentrations were significantly higher in all intervention groups (183 ± 91, 190 ± 105, and 206 ± 89 µg/L for 1.2, 2.4, and 10 mg, respectively) compared with the placebo group (153 ± 85 µg/L; P < 0.0001) and did not significantly differ from each other. CONCLUSIONS: A supplemental thiamine dose of 2.35 mg/d was required to achieve a milk total thiamine concentration of 191 µg/L. However, 1.2 mg/d for 22 wk was sufficient to increase milk thiamine concentrations to similar levels achieved by higher supplementation doses (2.4 and 10 mg/d), and comparable to those of healthy mothers in regions without beriberi. This trial was registered at clinicaltrials.gov as NCT03616288.
RCT Entities:
BACKGROUND: Infantile beriberi-related mortality is still common in South and Southeast Asia. Interventions to increase maternal thiamine intakes, and thus human milk thiamine, are warranted; however, the required dose remains unknown. OBJECTIVES: We sought to estimate the dose at which additional maternal intake of oral thiamine no longer meaningfully increased milk thiamine concentrations in infants at 24 wk postpartum, and to investigate the impact of 4 thiamine supplementation doses on milk and blood thiamine status biomarkers. METHODS: In this double-blind, 4-parallel arm randomized controlled dose-response trial, healthy mothers were recruited in Kampong Thom, Cambodia. At 2 wk postpartum, women were randomly assigned to consume 1 capsule, containing 0, 1.2 (estimated average requirement), 2.4, or 10 mg of thiamine daily from 2 through 24 weeks postpartum. Human milk total thiamine concentrations were measured using HPLC. An Emax curve was plotted, which was estimated using a nonlinear least squares model in an intention-to-treat analysis. Linear mixed-effects models were used to test for differences between treatment groups. Maternal and infant blood thiamine biomarkers were also assessed. RESULTS: In total, each of 335 women was randomly assigned to1 of the following thiamine-dose groups: placebo (n = 83), 1.2 mg (n = 86), 2.4 mg (n = 81), and 10 mg (n = 85). The estimated dose required to reach 90% of the maximum average total thiamine concentration in human milk (191 µg/L) is 2.35 (95% CI: 0.58, 7.01) mg/d. The mean ± SD milk thiamine concentrations were significantly higher in all intervention groups (183 ± 91, 190 ± 105, and 206 ± 89 µg/L for 1.2, 2.4, and 10 mg, respectively) compared with the placebo group (153 ± 85 µg/L; P < 0.0001) and did not significantly differ from each other. CONCLUSIONS: A supplemental thiamine dose of 2.35 mg/d was required to achieve a milk total thiamine concentration of 191 µg/L. However, 1.2 mg/d for 22 wk was sufficient to increase milk thiamine concentrations to similar levels achieved by higher supplementation doses (2.4 and 10 mg/d), and comparable to those of healthy mothers in regions without beriberi. This trial was registered at clinicaltrials.gov as NCT03616288.
Authors: Kyly C Whitfield; Crystal D Karakochuk; Hou Kroeun; Daniela Hampel; Ly Sokhoing; Benny B Chan; Mam Borath; Prak Sophonneary; Judy McLean; Aminuzzaman Talukder; Larry D Lynd; Eunice C Y Li-Chan; David D Kitts; Lindsay H Allen; Timothy J Green Journal: JAMA Pediatr Date: 2016-10-03 Impact factor: 16.193
Authors: Lindsay H Allen; Daniela Hampel; Setareh Shahab-Ferdows; Maria Andersson; Erica Barros; Andrew M Doel; Kamilla Gehrt Eriksen; Sophie Hilario Christensen; Munirul Islam; Gilberto Kac; Farhana Khanam Keya; Kim F Michaelsen; Daniela de Barros Mucci; Fanta Njie; Janet M Peerson; Sophie E Moore Journal: Curr Dev Nutr Date: 2021-09-20
Authors: Megan W Bourassa; Filomena Gomes; Kerry S Jones; Albert Koulman; Andrew M Prentice; Carla Cerami Journal: Ann N Y Acad Sci Date: 2021-09-20 Impact factor: 6.499
Authors: Bridget E Young; Jamie Westcott; Jennifer Kemp; Lindsay Allen; Daniela Hampel; Ana L Garcés; Lester Figueroa; Shivaprasad S Goudar; Sangappa M Dhaded; Manjunath Somannavar; Sarah Saleem; Sumera Aziz Ali; K Michael Hambidge; Nancy F Krebs Journal: Front Nutr Date: 2021-12-23
Authors: Jeffrey R Measelle; Dare A Baldwin; Jelisa Gallant; Kathleen Chan; Tim J Green; Frank T Wieringa; Mam Borath; Sophonneary Prak; Daniela Hampel; Setareh Shahab-Ferdows; Lindsay H Allen; Hou Kroeun; Kyly C Whitfield Journal: Ann N Y Acad Sci Date: 2021-06-07 Impact factor: 6.499